“Practice-changing” Results: Long-term Advanced Melanoma Survival Dramatically Improves on Immunotherapy
About half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors survive cancer-free for 10 years or more, according to follow-up data from CheckMate -067 presented at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain and simultaneously published in The New England Journal of Medicine. At 10 […]